Here’s Why SGA U.S. Large Cap Growth Strategy Sold Novo Nordisk (NVO)

2 hours ago 2

Soumya Eswaran

Fri, January 2, 2026 astatine 6:29 AM CST 3 min read

Sustainable Growth Advisers (SGA), an concern absorption company, released its third-quarter capitalist missive for its “U.S. Large Cap Growth Strategy.” A transcript of the missive tin beryllium downloaded here. The portfolio returned -1.3% (Gross) and -1.4% (Net) successful the 3rd quarter, compared to a 10.5% instrumentality for the Russell 1000 Growth Index and an 8.1% instrumentality for the S&P 500 Index. SGA’s concern nonsubjective is to put successful high-quality maturation businesses expected to execute accordant mid-teens net growth, accompanied by unchangeable gross and currency flow. However, successful Q3, the marketplace enactment was adverse for SGA’s concern benignant arsenic lower-quality stocks and cyclical industries outperformed. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, the SGA U.S. Large Cap Growth Strategy highlighted stocks specified arsenic Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages successful the probe and development, manufacture, and organisation of pharmaceutical products. The one-month instrumentality of Novo Nordisk A/S (NYSE:NVO) was 6.02%, and its shares mislaid 41.86% of their worth implicit the past 52 weeks. On December 31, 2025, Novo Nordisk A/S (NYSE:NVO) banal closed astatine $50.88 per share, with a marketplace capitalization of $226.084 billion.

SGA U.S. Large Cap Growth Strategy stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 3rd 4th 2025 capitalist letter:

"In July, we liquidated our presumption successful Novo Nordisk A/S (NYSE:NVO) and initiated a presumption successful Nike. We sold Novo Nordisk retired of the portfolio owed to 2 concerns that made america question the company’s quality to present semipermanent growth.